- Select a blog category
By Karen Taylor and Krissie Ferris, Centre for Health Solutions
The COVID-19 pandemic is first and foremost a human tragedy, affecting billions of citizens and millions of healthcare staff across the world. The UK Government’s healthcare response has largely been focussed on helping the NHS’s to manage, as far as possible, the predicted increase in hospital demand. This includes social distancing and lockdowns to minimise the spread of infections; building more hospital capacity; and procuring the diagnostic, personal protection equipment and treatments to deal with those who do become infected. Meanwhile, healthcare providers are having to re-consider how best to meet the needs of patients who fear they may have COVID-19, as well as the many others who require new and ongoing support, advice and treatments, while at the same time reducing the need for face to face consultations. As a result, many providers are rapidly embracing digital technologies to triage, support and, where possible, treat patients remotely and help clinicians work more effectively.
By Karen Taylor, Director, Centre for Health Solutions
Our previous reports have highlighted the increasing number of innovations that have led to life-saving and life-enhancing clinical treatments and how, over the past 30 or so years, healthcare has moved from treating infectious or communicable diseases to managing a ‘tidal wave’ of complex age and behaviour related, non-communicable, diseases.1 This transition was made possible by the development and widespread use of vaccines and antibiotics which dramatically reduced the prevalence and improved outcomes for most infectious diseases. Today, this scenario has been turned on its head as people across the world face the unrelenting human and economic impact from a novel, infectious, coronavirus SARS-CoV-2 (named COVID-19 disease). On 11th March the World Health Organisation (WHO) declared COVID-19 a pandemic, and the biopharma industry is now in a race to develop both preventive and therapeutic interventions.
By Pratik Avhad, Senior Analyst, Insight
The Indian pharmaceutical (pharma) industry has an annual revenue of US$38 billion – globally it’s the third largest in the world by volume and 11th by value. It comprises over 3,000 pharma companies and 10,500 manufacturing facilities. It also produces drugs at around a third of the US costs and half of the European costs. Moreover, Indian pharma companies supply around 20 per cent of the worlds’ generics and 50 per cent of its vaccines.1,2 This is the first of three blogs exploring the past, present and future of the Indian pharma market. This first blog examines the evolution of the industry, with subsequent ones exploring the transformations now underway, and the likely future for the industry.
By Krissie Ferris, Research Analyst, Centre for Health Solutions
As demonstrated in our recent report, ‘Realising digital-first primary care: Shaping the future of UK healthcare’, digital technology is transforming everyone’s relationship with healthcare. It is improving our access to health information and advice, helping us to connect more readily with healthcare professionals, and enabling us to track and manage our own health and wellbeing. However, to date, when it comes to women’s health, innovations have historically been underfunded and under supported. This is set to change with the rise of ‘FemTech’, an umbrella term for wearables, smartphone apps, diagnostics and other products designed to enhance women’s health and wellbeing. In recognition of last Sunday’s International Women’s Day, this week’s blog highlights why increasing investment in FemTech innovation is set to pay dividends!
By Maria João Cruz, Research Analyst, and Dr Francesca Properzi, PhD, Research Manager, Centre for Health Solutions
February 29, a pretty rare date, was this year’s Rare Disease Day, a campaign to raise awareness among the public and policy makers on rare diseases and how they impact the lives of patients and their loved ones.1 Indeed, the advocacy, commitment and tenacity of rare disease patient organisations have played a critical role in elevating ‘rare diseases’ as an emerging global public health priority. Particularly in advocating for legislation to develop drugs and treatment programmes that will meet patients’ needs. In today’s blog we highlight the importance of rare diseases and, in particular, the opportunities that artificial intelligence (AI) tools offer to speed-up the discovery of new treatments.
By Dr Francesca Properzi, PhD, Research Manager and Krissie Ferris, Research Analyst, Centre for Health Solutions
Primary care, particularly general practice, has been the cornerstone of the NHS since its inception. Over the past decade, increasing demand and capacity challenges have left many staff with unmanageable workloads. In recognition of these challenges, the NHS Long Term Plan, published in January 2019, identifies digital transformation as a national priority. Our latest report, ‘Realising digital-first primary care: Shaping the future of UK healthcare’, highlights the challenges in achieving the policy ambition for a digital-first, primary care service and the key steps needed to speed up the adoption of technology by patients, staff and the wider healthcare system.
By Juan Salcines Gomez-Pardo, Consultant, Monitor Deloitte
Small to medium sized life sciences companies are now at the forefront of innovation in the search for new cures and hope for patients. However, many biotech and medtech companies face significant challenges in navigating the business life cycle. Monitor Deloitte colleagues Li Xiaofeng, Hanno Ronte and James Forsyth have recently published our latest thinking on ‘Biotech-in-a-boxTM: ‘How to ‘ACE’ geographical expansion in Europe’. This report introduces a three-step game plan to support biotech and medtech companies to thrive in an increasingly challenging environment, de-risk attempts to scale up adoption of technologies and improve success in geographical expansion. This week’s blog by our colleague, Juan Salcines, highlights the key findings from this report, based on his recent experience working with biotech companies across Europe.
By Dr Francesca Properzi, PhD. Research Manager, and Maria João Cruz, Research Analyst, Centre for Health Solutions
This week we launched the third report in our series on the impact of artificial intelligence (AI) across the biopharma value chain. This latest report, Intelligent clinical trials: Transforming through AI-enabled engagement, explores how AI, in particular machine learning and natural language processing, can reduce clinical trial cycle times while reducing the costs and improving the productivity and outcomes of clinical development. In this blog, we highlight the main takeaways from our report.
By Maria João Cruz, Research Analyst, Centre for Health Solutions
Tuesday, 4th February, was the 20th World Cancer Day, a day that unites people, communities and entire countries to raise awareness and take action to reduce the global burden and impact of cancer. This year marks the mid-point of a three year campaign, led by the Union for International Cancer Control (UICC), ‘I Am and I Will’. This campaign is seen as an empowering ‘call-to-action’, urging everyone to commit personally to taking action now to impact the future.1 Today, I want to share with you my reflections on the importance of this day.
By Dr Jane Halpin and Dr Arvind Madan
Since July 2019, as part of the NHS Long Term Plans (LTPs) ambition to develop integrated health and care, all general practices in England have come together to form one of 1,250 or so Primary Care Networks (PCNs). While this isn’t the first attempt to encourage greater cooperation between practices, it is the first time in NHS history that real terms funding for primary and community health services is guaranteed to grow at a faster rate than that of the overall NHS budget, including £1.8 billion to support the establishment of PCNs.
By David Tullett, Consultant, Deloitte MCS Limited
Earlier this month our colleagues published their report, The role of innovative and unfamiliar acquisitions in unlocking R&D productivity, which looks at the impact of M&A on the pharma landscape and outlines how external innovation is impacting pharmaceutical R&D and the reasons behind the projected growth in deal volume for 2020. This week’s blog by our colleague, David Tullett, who worked closely on the above report with Heena Dodhia and Mark Stockbridge, provides his view on the key takeaways.